CNBC Top NewsCodex · 实盘不做把握 6/10
北京时间·🕒 发布 19:38:55时区推断·⟳ 抓取 19:39:12·⚡ 决策 08-04 20:06:11 +26m59s·83.9 天前
辉瑞二季度业绩好于预期并小幅上调全年收入指引下限
辉瑞二季度调整后EPS为0.77美元、收入150.3亿美元，均高于LSEG一致预期，但全年调整后EPS指引仍维持2.80至3.00美元。
📄 原文CNBC Top News↗ 原文
Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs
Pfizer on Tuesday reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, c…
不做 辉瑞（PFE.US）
不做：这是财报类可预期事件，虽然季度业绩超预期，但全年EPS指引未上修、收入指引只是小幅抬高下限且Covid产品预期下调，对辉瑞这种大市值药企缺乏足够短线edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 辉瑞投资者关系页列出2026年8月4日二季度业绩活动和公告入口，确认这是公司正式财报事件；页面未抓到精确公告分钟。
- CNBC报道辉瑞二季度收入和调整后EPS超预期，并把全年收入指引下限上调至605亿美元。
- WSJ同步报道收入同比增长但GAAP录得亏损，非Covid增长抵消Covid产品下滑。
- Barron's强调非Covid组合改善与BioNTech因Covid需求走弱而承压，说明市场解读并非纯利好。
关键理由
- 辉瑞二季度调整后EPS为0.77美元、收入150.3亿美元，均高于LSEG一致预期，但全年调整后EPS指引仍维持2.80至3.00美元。
- 全年收入指引仅把下限从595亿美元上调至605亿美元，上限不变且相对2025年626亿美元收入仍大致持平或略降，增量对约1400亿美元市值缺乏短线重定价弹性。
- 非Covid产品表现较强抵消了Covid业务下调，但Covid产品全年预期从约50亿美元降至40亿美元，事件净影响不是强单边利好。
主要风险
- 若10:00 ET业绩电话会上管理层上调管线、成本节约或资本回报预期，可能使当前不做判断偏保守。
- 药品管线和Metsera肥胖症资产仍是中长期变量，但本次财报没有给出足够可量化的新增商业化拐点。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-04 · 影响 weakens
发现反向约束：全年EPS指引未上调，Covid产品收入预期从约50亿美元降至40亿美元。
检索:Pfizer Q2 2026 earnings Covid products guidance lowered EPS guidance unchanged 原文 ↗
原文全文
展开原文 · 1,393 字
Pfizer on Tuesday reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, citing the stronger-than-expected performance of non-Covid products.
The company is now expecting full-year revenue to total $60.5 billion to $62.5 billion, which compares to a previous outlook of $59.5 billion to $62.5 billion. That sales range would still be roughly flat or down slightly compared with 2025 revenue of $62.6 billion.
Pfizer said it cut its full-year revenue expectation for its Covid products – the vaccine and antiviral pill Paxlovid – to $4 billion, down from around $5 billion previously.
The pharmaceutical giant reiterated its full-year adjusted profit outlook of between $2.80 and $3 per share.
Here's what the company reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:
- Earnings per share: 77 cents adjusted vs. 68 cents expected
- Revenue: $15.03 billion vs. $14.41 billion expected
The pharmaceutical giant is looking to longer-term investments in its pipeline, including its recent $10 billion acquisition of the obesity biotech Metsera, to counter waning Covid product sales and declines from older drugs. Investors are focused on several crucial data releases from Pfizer this year, including data on a combination regimen that includes its GLP-1 injection and an amylin asset.
The company is now expecting full-year revenue to total $60.5 billion to $62.5 billion, which compares to a previous outlook of $59.5 billion to $62.5 billion. That sales range would still be roughly flat or down slightly compared with 2025 revenue of $62.6 billion.
Pfizer said it cut its full-year revenue expectation for its Covid products – the vaccine and antiviral pill Paxlovid – to $4 billion, down from around $5 billion previously.
The pharmaceutical giant reiterated its full-year adjusted profit outlook of between $2.80 and $3 per share.
Here's what the company reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:
- Earnings per share: 77 cents adjusted vs. 68 cents expected
- Revenue: $15.03 billion vs. $14.41 billion expected
The pharmaceutical giant is looking to longer-term investments in its pipeline, including its recent $10 billion acquisition of the obesity biotech Metsera, to counter waning Covid product sales and declines from older drugs. Investors are focused on several crucial data releases from Pfizer this year, including data on a combination regimen that includes its GLP-1 injection and an amylin asset.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。